Michael Lee

Array ( [id] => 14498009 [patent_doc_number] => 20190192659 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-06-27 [patent_title] => FORMULATIONS OF BENDAMUSTINE [patent_app_type] => utility [patent_app_number] => 16/291401 [patent_app_country] => US [patent_app_date] => 2019-03-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7708 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 71 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16291401 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16876807 [patent_doc_number] => 11026927 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-06-08 [patent_title] => Pharmaceutical combination comprising a selective S1P1 receptor agonist [patent_app_type] => utility [patent_app_number] => 16/277829 [patent_app_country] => US [patent_app_date] => 2019-02-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 4778 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 67 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16277829 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15206017 [patent_doc_number] => 20190365695 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-12-05 [patent_title] => ANAPLEROTIC THERAPY OF HUNTINGTON DISEASE AND OTHER POLYGLUTAMINE DISEASES [patent_app_type] => utility [patent_app_number] => 16/267210 [patent_app_country] => US [patent_app_date] => 2019-02-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9465 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 27 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16267210 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14893691 [patent_doc_number] => 20190290611 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-09-26 [patent_title] => CIS-GNETIN H AND TRANS-GNETIN H AS THERAPEUTIC AGENTS [patent_app_type] => utility [patent_app_number] => 16/265789 [patent_app_country] => US [patent_app_date] => 2019-02-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17003 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16265789 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14306243 [patent_doc_number] => 20190142825 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-05-16 [patent_title] => Role of N-2-Hydroxy-Ethyl-Piperazine-N'-2-Ethane Sulfonic Acid (HEPES) in Pain Control and Reversal of Demyelinization Injury [patent_app_type] => utility [patent_app_number] => 16/247233 [patent_app_country] => US [patent_app_date] => 2019-01-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8739 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 88 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16247233 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16555634 [patent_doc_number] => 20210000782 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-01-07 [patent_title] => APPLICATION OF DROFENINE OR SALT THEREOF TO PREPARATION OF MEDICINE FOR TREATING PERIPHERAL NEURON AXONAL INJURY AND PERIPHERAL RELATED NEUROPATHY [patent_app_type] => utility [patent_app_number] => 16/980429 [patent_app_country] => US [patent_app_date] => 2019-01-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 2888 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -2 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16980429 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14306199 [patent_doc_number] => 20190142803 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-05-16 [patent_title] => Treatment of Mild and Moderate Alzheimer's Disease [patent_app_type] => utility [patent_app_number] => 16/242757 [patent_app_country] => US [patent_app_date] => 2019-01-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12962 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 31 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16242757 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15206025 [patent_doc_number] => 20190365699 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-12-05 [patent_title] => Treatment of Kidney Tumors by Intratumoral Injection of Taxane Particles [patent_app_type] => utility [patent_app_number] => 16/239531 [patent_app_country] => US [patent_app_date] => 2019-01-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22787 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16239531 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14960603 [patent_doc_number] => 20190307779 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-10-10 [patent_title] => NOVEL FORMULATIONS [patent_app_type] => utility [patent_app_number] => 16/236817 [patent_app_country] => US [patent_app_date] => 2018-12-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 64608 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16236817 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14210473 [patent_doc_number] => 20190117621 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-04-25 [patent_title] => STABILIZED STATIN FORMULATIONS [patent_app_type] => utility [patent_app_number] => 16/231132 [patent_app_country] => US [patent_app_date] => 2018-12-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7352 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16231132 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19256836 [patent_doc_number] => 12016865 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-06-25 [patent_title] => Methods and pharmaceutical compositions for treating candida auris in blood [patent_app_type] => utility [patent_app_number] => 16/229898 [patent_app_country] => US [patent_app_date] => 2018-12-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 6647 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 72 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16229898 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16523723 [patent_doc_number] => 20200397803 [patent_country] => US [patent_kind] => A9 [patent_issue_date] => 2020-12-24 [patent_title] => TREATMENT OF FIBROSIS USING FXR LIGANDS [patent_app_type] => utility [patent_app_number] => 16/228944 [patent_app_country] => US [patent_app_date] => 2018-12-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21668 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -4 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16228944 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16523723 [patent_doc_number] => 20200397803 [patent_country] => US [patent_kind] => A9 [patent_issue_date] => 2020-12-24 [patent_title] => TREATMENT OF FIBROSIS USING FXR LIGANDS [patent_app_type] => utility [patent_app_number] => 16/228944 [patent_app_country] => US [patent_app_date] => 2018-12-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21668 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -4 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16228944 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14210487 [patent_doc_number] => 20190117628 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-04-25 [patent_title] => Ifetroban Treatment for Systemic Sclerosis [patent_app_type] => utility [patent_app_number] => 16/221546 [patent_app_country] => US [patent_app_date] => 2018-12-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7119 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 36 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16221546 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16655905 [patent_doc_number] => 20210052541 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-02-25 [patent_title] => Application of (5R)-5-Hydroxytriptolide in Preparation of Drugs [patent_app_type] => utility [patent_app_number] => 16/969594 [patent_app_country] => US [patent_app_date] => 2018-12-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4325 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 27 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16969594 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16755294 [patent_doc_number] => 10973820 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-04-13 [patent_title] => Compounds for treatment of diseases related to DUX4 expression [patent_app_type] => utility [patent_app_number] => 16/217184 [patent_app_country] => US [patent_app_date] => 2018-12-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 5 [patent_no_of_words] => 15240 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 43 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16217184 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18792588 [patent_doc_number] => 11826321 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-11-28 [patent_title] => Cyclobenzaprine treatment for agitation, psychosis and cognitive decline in dementia and neurodegenerative conditions [patent_app_type] => utility [patent_app_number] => 16/215952 [patent_app_country] => US [patent_app_date] => 2018-12-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11760 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 132 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16215952 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14464451 [patent_doc_number] => 20190183865 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-06-20 [patent_title] => NSD FAMILY INHIBITORS AND METHODS OF TREATMENT THEREWITH [patent_app_type] => utility [patent_app_number] => 16/213564 [patent_app_country] => US [patent_app_date] => 2018-12-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 41052 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16213564 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14182715 [patent_doc_number] => 20190111062 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-04-18 [patent_title] => DOSING REGIMEN FOR SEDATION WITH CNS 7056 (REMIMAZOLAM) [patent_app_type] => utility [patent_app_number] => 16/213879 [patent_app_country] => US [patent_app_date] => 2018-12-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15255 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16213879 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14649255 [patent_doc_number] => 20190231756 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-01 [patent_title] => THERAPEUTIC COMPOSITIONS CONTAINING HARMINE AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 16/213774 [patent_app_country] => US [patent_app_date] => 2018-12-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34729 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -2 [patent_words_short_claim] => 95 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16213774 [rel_patent_id] =>[rel_patent_doc_number] =>)